Jessica Abreu-Garcia, MD
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,027 of the $29,966 with a category attached, or 70.2%. AbbVie accounts for 66.1% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $21,624, more than ten times the $274 reported in 2019. Among neurology clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 83 payments — averaging $361.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$20K
- Pfizer Chile S.A.$4K
- Pfizer$4K
- Biogen$768
- EMD Serono, Inc.$250
- PBG Puerto Rico LLC$222
- plus $1K from 17 others
What the payments were for
- Consulting fees$2,5759%
- Speaking & faculty fees$21,02770%
- Travel & lodging$3,17811%
- Food & beverage$3,18711%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 26 | $19,811 |
| Pfizer Chile S.A. | 1 | $3,900 |
| Pfizer | 2 | $3,775 |
| Biogen | 11 | $768 |
| EMD Serono, Inc. | 2 | $250 |
| PBG Puerto Rico LLC | 7 | $222 |
| E.r. Squibb & Sons, L.L.C. | 3 | $215 |
| ANI Pharmaceuticals, Inc. | 9 | $178 |
| Amneal Pharmaceuticals LLC | 3 | $171 |
| Teva Pharmaceuticals USA, Inc. | 2 | $100 |
| Amgen(2 entities) | 2 | $88 |
| Eli Lilly | 1 | $77 |
| Eli Lilly Export S.A. Puerto Rico Branch | 1 | $76 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $66 |
| Novartis | 3 | $65 |
| GSK | 1 | $51 |
| Biohaven Pharmaceuticals, Inc. | 1 | $28 |
| Acorda Therapeutics, Inc | 1 | $24 |
| AstraZeneca | 1 | $24 |
| Johnson & Johnson | 1 | $21 |
| Boston Scientific | 1 | $20 |
| Genentech USA, Inc. | 1 | $18 |
| Adamas Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,966 in reported general payments places this provider in the 90th percentile of 129 neurology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 68 | $92,216 |
| Emgality PenGalcanezumab-Gnlm | 69 | $56,153 |
| Nurtec OdtRimegepant Sulfate | 31 | $31,381 |
| Emgality SyringeGalcanezumab-Gnlm | 17 | $30,433 |
| Aimovig AutoinjectorErenumab-Aooe | 17 | $13,059 |
| Pyridostigmine Bromide | 16 | $1,730 |
| Carbamazepine ErCarbamazepine | 32 | $1,664 |
| Eletriptan HbrEletriptan Hydrobromide | 24 | $1,507 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 31 | $1,054 |
| RizatriptanRizatriptan Benzoate | 60 | $1,040 |
| Memantine Hcl | 41 | $772 |
| Gabapentin | 105 | $653 |
| Donepezil Hcl | 77 | $640 |
| Primidone | 43 | $599 |
| Levetiracetam | 26 | $504 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy | $19,811 | $92,21668 claims |
| PfizerNurtec Odt | $3,775 | $31,38131 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $171 | $1,73016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 129 neurology providers in Puerto Rico.
Other neurology in Ponce
- Javier OteroPonce$2K
- Carlos Berrios RosadoPonce$2K
- Angel ChineaGuaynabo$1.7M
- Jose Avila OrnelasCaguas$538K
- Franchesca Fiorito-TorresSan Juan$453K
- Patricia de JesusCaguas$310K
- Mari GarciaSan Juan$138K
- Cristina Cabret-AymatSan Juan$108K
- Gishlaine Alfonso MendezSan Juan$53K
- Laura Surillo-DahdahGuaynabo$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.